摘要
目的:观察重组人血管内皮抑素(恩度,Recombinant human endostatin,Endostar,YH-16)联合XELOX方案(奥沙利铂+卡培他滨)治疗进展期胃癌(advanced gastric cancer,AGC)的近期疗效和远期疗效及安全性。方法:采用回顾性病例研究方法,60例进展期胃癌患者分为两组,实验组29例给予恩度联合XELOX方案治疗,对照组31例仅给予XELOX方案治疗,两组患者均至少接受2个周期的化疗。观察两组患者的完全缓解(complete remission,CR)、部分缓解(partial remission,PR)、稳定(stable disease,SD)和疾病进展(progressive disease,PD)情况,以CR+PR为有效率(remission rate,RR),以CR+PR+SD为临床受益率(clinical benefit rate,CBR),以及中位肿瘤进展时间(time to pro-gression,TTP),同时评价两组患者治疗前后生活质量改善情况(包括ECOG评分变化及临床症状缓解率)及毒副反应。结果:入组病例特点:实验组ECOG评分(1.61±0.29)较对照组(1.35±0.22)高,有统计学差异(P<0.05)。实验组和对照组组RR分别为48.27%和22.58%(P<0.05),CBR分别为79.31%和48.38%(P<0.05),TTP分别为7.4个月和3.7个月(P<0.05)。治疗后实验组ECOG评分为(1.26±0.32),对照组ECOG评分为(1.06±0.27),均较治疗前明显降低,具有统计学差异(P<0.05),实验组的临床症状缓解率除腹胀外均较对照组高,腹痛缓解率分别为92.6%和60.0%,进食梗噎缓解率分别为94.1%和33.3%,食欲不佳缓解率分别为92.6%和66.7%,有统计学差异(P<0.05)。两组患者治疗后中、重度不良反应发生率比较,差异无统计学意义。结论:恩度联合XELOX方案治疗进展期胃癌安全有效、耐受性良好,值得临床推广应用。
Objective：To observe the clinical treated outcome of short-long term and safety of recombinant human vascular endostatin（endostar,YH-16）combined with XELOX（oxaliplatin＋capecitabine）regimen for Patients with advanced gastric carcinoma.Methods：Sixty patients with relapse of stageⅢ and Ⅳ advanced gastric carcinoma were divided into the test groups in which 29 cases received endostar plus XELOX regimen,and the controlgroup in which 31 cases were given XELOX chemotherapy only.All the patients received treatment at least 2 cycles.The treated results were assessed on basis of the criteria of complete remission rate（CR）,partial remissionrate（PR）,stable disease（SD;and progressive disease（PD）,and CR＋PR was defined as remission rate（RR）and CR＋PR＋SD was defined as clinical benefit rate（CBR）.The median time to tumor progression（TTP）,quality of life（include the variation of ECOG and the relief rate of clinical symptoms）and side reactions were evaluated.Results：ECOG level in test group was higher（1.61＋0.29）than that（1.35＋0.22）in control group（P0.05）.The RR and CBR was 48.27%,79.31%for testing group and 22.58%and 48.38% for control group（P0.05）.TTP was 7.4 or 3.7 months for the both groups（P0.05）.ECOG was（1.26±0.32）in test group and（1.06±0.27）in control group（P0.05）after treatment.As compared with control group,relief rate of clinical symptoms in test group was higher than that in control group but abdominal distension,and the relief rate of abdominal pain was 92.6% and 60.0%,the relief rate of anorexia was 92.6% and 66.7%（P0.05）,respectively.No statistical differences in main side reactions between test group and control group（P0.05）.Conclusions：The endostar combined with XELOX regimen is effective,safe,and well tolerated in the treatment of advanced gastriccarcinoma.
出处
《青海医药杂志》
2012年第8期2-5,共4页
Qinghai Medical Journal
